Anteris Technologies Share Price and Company Fundamentals
Last traded: Today at 5:38 AM
Anteris Technologies Ltd operates as a structural heart company. The company offers ADAPT technology, which re-engineers xenograft tissue into a pure collagen scaffold; and develops DurAVRTM, a 3D single piece aortic valve for the treatment of aortic stenosis. It also researches and develops regenerative medicine and immunotherapies. The company was formerly known as Admedus Limited and changed its name to Anteris Technologies Ltd in May 2020. Anteris Technologies Ltd was incorporated in 1999 and is based in Toowong, Australia.
|Primary activities||Innovative Healthcare Solutions - developing, investing and delivering leading edge medical technologies.|
|Industry / Sector||Medical Devices / Healthcare|
|Mailing address||Toowong Tower Suite 302 Level 3 9 Sherwood Road Toowong QLD 4066 Australia|
|Phone / Fax||61 1300 550 310 / 61 1300 972 437|
|Share registry||COMPUTERSHARE INVESTOR SERVICES PTY LIMITED|
Anteris Technologies does not pay dividends.
As of May 2021, following are the company executives and directors listed on Anteris Technologies.
|Mr. Wayne G. Paterson||CEO, MD & Exec. Director||53||1.52M|
|Mr. Matthew McDonnell||Chief Financial Officer||500.89k|
|Mr. David St. Denis||Chief Operating Officer||889.32k|
|Ms. Martha Engel||Gen. Counsel||464.14k|
|Mr. Stephen Denaro||Independent Non-Exec. Director & Company Sec.||146.67k|
|Mr. Chris Olig||Bus. Devel. and Portfolio Planning Director|
|Mr. Danny Zanardo||Commercial Director of International|
|Prof. Ian Hector Frazer||Exec.|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Anteris Technologies is 56.91M and its enterprise value is 52.92M. The enterprise value to revenue ratio of AVR is 7.48.
The AVR's stocks Beta value is 0.84 making it 16% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Anteris Technologies (AVR)
- Ansell (ANN)
- Cochlear (COH)
- Estia Health (EHE)
- Fisher & Paykel Healthcare Corporation (FPH)
- Healius (HLS)
- Nanosonics (NAN)
- Polynovo (PNV)
- Pro Medicus (PME)
- Ramsay Health Care (RHC)
- Resmed Inc (RMD)
- Sonic Healthcare (SHL)
Anteris Technologies (ASX:AVR) Frequently Asked Questions
1. What is Anteris Technologies's Stock Symbol?
Anteris Technologies trades on ASX under the ticker symbol "AVR".
2. What is Anteris Technologies's stock price today?
One share of AVR stock can currently be purchased for approximately $8.59.
3. How can I contact Anteris Technologies?
Anteris Technologies's mailing address is Toowong Tower Suite 302 Level 3 9 Sherwood Road Toowong QLD 4066 Australia. The company can be reached via phone at 61 1300 550 310.
4. What is Anteris Technologies's official website?
The official website of Anteris Technologies is http://www.anteristech.com.
5. Which share registry manages Anteris Technologies's stock?
Anteris Technologies's stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.